New Data at the ASCO20 Virtual Scientific Program Reflects Genentech’s Commitment to Accelerating Progress in Cancer Care

[unable to retrieve full-text content]SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 19 approved and investigational medicines across 21 cancer types will be presented at the ASCO20 Virtual Scientific Program organized by the American Society of Clinical Oncology (ASCO), which will be held May 29-31, 2020. A total of 120 abstracts that include a Roche medicine will be presented at this year’s meeting. “At ASCO,
Source

About the Author: Biotech Today

You might like